Evidence map›Paper›PMID 35833737›Full record

SynthesisAnnals of medicine2022

Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials.

Shao-Huan Lan, Chi-Kuei Hsu, Chih-Cheng Lai, Shen-Peng Chang, Li-Chin Lu, Shun-Hsing Hung, Wei-Ting Lin

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Trial
  5. Trial
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Shao-Huan LanSchool of Pharmaceutical Sciences and Medical Technology, Putian University, Putian, China.ORCID 0000-0002-8663-3161
Chi-Kuei HsuDepartment of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Chih-Cheng LaiDivision of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.ORCID 0000-0002-6334-2388
Shen-Peng ChangYijia Pharmacy, Tainan, Taiwan.ORCID 0000-0002-9361-4348
Li-Chin LuSchool of Management, Putian University, Putian, China.ORCID 0000-0002-4289-0780
Shun-Hsing HungDivision of Urology, Department of Surgery, Chi-Mei Hospital, Chia Li, Tainan, Taiwan.
Wei-Ting LinDepartment of Orthopedic, Chi Mei Medical Center, Tainan, Taiwan.ORCID 0000-0003-2154-2215
Chi Mei Medical Center · TWPutian University · CNE-Da Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis meta-analysis aimed to assess the usefulness of colchicine in patients with COVID-19.

methodsPubMed, Web of Science, Ovid MEDLINE, the Cochrane Library, Embase, and Clinicaltrials.gov were searched for relevant randomised controlled trials (RCTs) published between database inception and November 12, 2021. Only RCTs that compared the clinical efficacy and safety of colchicine with other alternative treatments or placebos in patients with COVID-19 were included.

resultsOverall, 7 RCTs involving 16,024 patients were included; 7,794 patients were in the study group receiving colchicine and 8,230 were in the control group receiving placebo or standard treatment. The study and control groups had similar risk of mortality (odds ratio [OR], 1.00; 95% CI, 0.91-1.09;

conclusionsColchicine does not improve clinical outcomes in patients with COVID-19, so it did not support the additional use of colchicine in the treatment of patients with COVID-19.Key messageColchicine could not reduce the mortality of patients with COVID-19.No significant difference was observed between the colchicine and comparators in terms of the need for non-invasive ventilation, need for mechanical ventilation, and length of hospital stay.Colchicine was associated with a higher risk of gastrointestinal adverse events.

Indexed as

COVID-19 Drug TreatmentColchicineHumansLength of StayRandomized Controlled Trials as TopicRespiration, ArtificialTreatment OutcomeColchicineColchicineCOVID-19mechanical ventilationmortalitynon-invasive ventilationSARS-CoV-2

Identifiers

PMID35833737
PMCPMC9291717
OpenAlexW4285489606

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.